Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Predicted Market Size Of The Antipsychotic Drugs Industry By 2029?

The market for antipsychotic drugs has seen robust growth in the past few years and is projected to expand from a value of $19.5 billion in 2024 to $21.25 billion in 2025, with a compound annual growth rate (CAGR) of 9.0%. Factors contributing to growth during the historical period include an increase in mental health disorders, the creation of second-generation antipsychotics, a rise in the elderly population, enhancements to healthcare infrastructure, and substantial research and development investments.

In the coming years, the market size for antipsychotic drugs is predicted to experience significant growth, potentially reaching “$30.39 billion by 2029 with a compound annual growth rate (CAGR) of 9.4%. This expected development during the forecast period can be linked to a rise in cases of schizophrenia and bipolar disorder, encouraging government policies and funding, a surge in the need for individualized medication, a concentration on minimizing side effects, and the expansion of mental health advocacy and support groups. The forecast period is likely to see key trends such as the incorporation of digital health tools for surveillance, the creation of groundbreaking mechanisms of action, a heightened attention to combined therapies, the application of pharmacogenomics for customized treatments, and a focus on patient-centric drug development.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18780&type=smp

What Market Forces Are Contributing To The Growth Of The Antipsychotic Drugs Market?

Advancement within the antipsychotic drug market is projected to be propelled by the rising prevalence of mental disorders. Typically, mental illnesses refer to ailments that significantly impact an individual’s thought processes, behavioral patterns, mood, and mental health. Various factors such as stress, societal pressure, inherent genetic tendencies, neurodevelopmental problems, biochemical imbalances, and physical health conditions can contribute to mental disorders. Antipsychotic medications address these issues by manipulating the activities of neurotransmitters – primarily dopamine and serotonin – which in return mitigate psychotic symptoms, stability mood, and augment cognitive and emotional function. For example, the Substance Abuse and Mental Health Services Administration (SAMHSA), a US-based public health organisation, found in a survey held in November 2023 that approximately 6% of adults, or about 15.4 million people aged 18 and older, reported experiencing serious mental illness (SMI). Subsequently, the Australian Institute of Health and Welfare declared in September 2024 that the number of Australians living with dementia is predicted to more than double from approximately 411,100 in 2023 to 849,300 by 2058, affecting an estimated 315,500 men and 533,800 women. Consequently, the escalating prevalence of mental disorders is attributing to the growth of the antipsychotic drug market.

Which Segments Define The Structure Of The Antipsychotic Drugs Market?

The antipsychotic drugs market covered in this report is segmented –

1) By Therapeutic Class: First Generation, Second Generation, Third Generation

2) By Disease: Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Other Diseases

3) By Distribution Channel: Hospital Pharmacies, Drug Stores, Online Pharmacies

Subsegments:

1) By First Generation: Typical Antipsychotics, Phenothiazines, Butyrophenones, Thioxanthenes, Dibenzoxazepines

2) By Second Generation: Atypical Antipsychotics, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripiprazole, Paliperidone, Lurasidone

3) By Third Generation: Partial Dopamine Agonists, Aripiprazole, Brexpiprazole, Cariprazine

What Strategic Shifts And Innovations Are Influencing The Antipsychotic Drugs Market?

Key players in the antipsychotic drug market are directing their efforts towards the production of innovative healthcare goods, such as atypical antipsychotic injectables to be administered subcutaneously. These solutions not only provide increased efficiency over conventional orally-taken medicines but also foster better patient compliance. Atypical antipsychotic injections administered beneath the skin serve as effective medications for mental disorders, helping to maintain level blood conditions and enhance symptom management. For instance, in April 2023, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical organization, teamed up with MedinCell SA, a French producer of biological and pharmaceutical products, to introduce UZEDY, a product that has received approval from U.S. Food and Drug Administration (FDA). UZEDY, an extended-release injectable variant of risperidone, is devised as a long-lasting subcutaneous injection capable of flexible administration intervals of one or two months. MedinCell’s exclusive SteadyTeq technology used in UZEDY ensures the steady dispersion of the drug, achieving therapeutic levels between 6-24 hours after injection. UZEDY displayed an up to 80% decrease in the probability of schizophrenia relapse in contrast with a placebo during clinical tests. The purpose of this drug is to deal with common adherence problems linked with oral antipsychotic medication, which frequently result in relapse.

Who Are The Most Influential Companies In The Antipsychotic Drugs Market?

Major companies operating in the antipsychotic drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Merck And Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Cipla Ltd., H. Lundbeck A/S, Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., Apotex Inc., Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Alkermes plc

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/antipsychotic-drugs-global-market-report

Which Region Is Forecasted To Lead The Antipsychotic Drugs Market In The Coming Years?

North America was the largest region in the antipsychotic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antipsychotic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=18780&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model